{"id":12789,"date":"2024-06-07T14:23:48","date_gmt":"2024-06-07T14:23:48","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=12789"},"modified":"2026-02-15T00:28:14","modified_gmt":"2026-02-14T22:28:14","slug":"safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/","title":{"rendered":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial"},"content":{"rendered":"
\n\"\"\n<\/div>\n
T\u00e9l\u00e9charger le poster<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

T\u00e9l\u00e9charger le poster<\/p>\n","protected":false},"author":2,"featured_media":12791,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[],"category_press":[],"year_press":[70],"class_list":["post-12789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-posters-fr","year_press-2024-2"],"acf":[],"yoast_head":"\nSafety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"T\u00e9l\u00e9charger le poster\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-07T14:23:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T22:28:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"223\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial\",\"datePublished\":\"2024-06-07T14:23:48+00:00\",\"dateModified\":\"2026-02-14T22:28:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/\"},\"wordCount\":25,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png\",\"articleSection\":[\"Posters\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/\",\"name\":\"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png\",\"datePublished\":\"2024-06-07T14:23:48+00:00\",\"dateModified\":\"2026-02-14T22:28:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png\",\"width\":500,\"height\":223},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/","og_locale":"fr_FR","og_type":"article","og_title":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma","og_description":"T\u00e9l\u00e9charger le poster","og_url":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/","og_site_name":"MaaT Pharma","article_published_time":"2024-06-07T14:23:48+00:00","article_modified_time":"2026-02-14T22:28:14+00:00","og_image":[{"width":500,"height":223,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial","datePublished":"2024-06-07T14:23:48+00:00","dateModified":"2026-02-14T22:28:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/"},"wordCount":25,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png","articleSection":["Posters"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/","url":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/","name":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png","datePublished":"2024-06-07T14:23:48+00:00","dateModified":"2026-02-14T22:28:14+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/06\/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png","width":500,"height":223},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/fr\/safety-tolerability-and-gut-microbiota-analysis-of-an-oral-microbiotherapy-in-amyotrophic-lateral-sclerosis-an-open-label-phase-1b-pilot-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/12789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=12789"}],"version-history":[{"count":2,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/12789\/revisions"}],"predecessor-version":[{"id":24075,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/12789\/revisions\/24075"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/12791"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=12789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=12789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=12789"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=12789"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=12789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}